Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896096 | 1.00 | MAPT (0.58) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL5923421 | 1.00 | MAPT (0.58) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL7980473 | 0.84 | DHODH (0.45) | MAPT | |
| SCHEMBL7512779 | 0.84 | DHODH (0.45) | MAPT | |
| SCHEMBL6142224 | 0.84 | DHODH (0.45) | MAPT | |
| SCHEMBL7112204 | 0.82 | MAPT (0.57) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1942388 | 0.82 | MAPT (0.57) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1942389 | 0.82 | MAPT (0.57) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL7974579 | 0.81 | MEN1 (0.44) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL5896001 | 0.81 | MAPT (0.56) | MAPTALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041690-B2 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC | 2006-01-05 | — | — | US | disclosed |
| EP-1532128-A1 | INHIBITORS OF HCV NS5B POLYMERASE | Pharmacia & Upjohn Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004002977-A1 | INHIBITORS OF HCV NS5B POLYMERASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, EIF5B, POLI | MAPT 3589/4885ALDH1A1 1400/4885LMNA 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.